Africa: Vaccines Delayed Are Vaccines Denied


“Vaccine equity is the challenge of our time,” Tedros Adhanom Ghebreyesus, Director-General of the World Health Organization (WHO), told the gathering in opening remarks. “And we are failing”at a special ministerial meeting of the Economic and Social Council.

Earlier, G7 leaders wrote a letter of support declaring that wealthier countries should pay the cost to vaccinate low and middle income countries.

Globally, indiscriminate inequity exists in the procurement and distribution of vaccines, which has hit the countries in Asia and Africa the most. According to the World Health Organization, among the 832 million vaccine doses that have been administered, 82% have gone to high- or upper-middle-income countries, while only 0.2% have been shipped to low-income countries

The United States announced that it would donate 500 million doses of the Pfizer vaccine to COVAX to supply COVID vaccine doses to countries in need. In addition, several countries pledged support to a waiver to intellectual property restrictions, which could allow countries to produce the vaccine generically to amplify production and supply.

While these are essential steps in the right direction, a global system in which poor countries are unable to develop and produce their own vaccines to match their demand is not sustainable; particularly when faced by potential future pandemics.

Stringent measures, with global solidarity and commitment to build global vaccine equity and ensure the last person gets the vaccine in rich and poor countries alike before the next global health crisis hits is the need of the hour. This is a time when internationalism wins over nationalism, and globalism works better than local.

Globally, indiscriminate inequity exists in the procurement and distribution of vaccines, which has hit the countries in Asia and Africa the most. According to the World Health Organization, among the 832 million vaccine doses that have been administered, 82% have gone to high- or upper-middle-income countries, while only 0.2% have been shipped to low-income countries.

According to a United Nations report, in high-income countries alone, 1 in 4 people have been vaccinated, a ratio that drops precipitously to 1 in 500 in low-income countries.

This inequitable vaccine access is rooted in the power, influence and the control of few rich countries who have determined vaccine allocation. Early on, despite COVAX’s commitment to vaccinate the world’s population, Western countries developed vaccines separately, in bulk, more than what was necessary, hoarded and vaccinated all, including their young people, who are considered less at risk.

Citizens of low income countries faced shortage, even those who were at risk for COVID-19. As a result, many countries have been left behind.

In the Global South, countries have welcomed and celebrated the ‘noble’ decision of rich countries to donate overstocked vaccines. However, we must take a step back to understand why countries need donations in the first place.

Our struggle to access vaccines is not a consequence of our present shortcomings but of our long histories–many of which are burdened with the legacy of violent colonialism. If poor countries need to rely on donated vaccines, it’s a sign that the global health system is not working. Global Health has failed in this Pandemic.

It’s not just about purchasing doses. A painful history of unequal power relations has shifted resources out of low- and middle-income countries to their high-income counterparts.

We are working against a persistent lack of support for the infrastructure that allows countries in the Global South to independently drive scientific development. Moreover, our material resources and human capital have supported northern economies for decades.

This is exacerbated by the problem of brain drain, in which talent is pulled from low- and middle-income countries to their high-income counterparts, perpetuating dependence and inequities. For example, it is estimated that researchers working internationally from low-income countries produce 10 times more patents than their compatriots at home.

Scientific and health sovereignty are strategic drivers of equitable access to health.

Rich countries are often lauded for aid and donations- progress can be made when we move from charity to rights-based models.

To sustain development efforts, international cooperation and collaboration that allows what countries need is international cooperation that enhances local capacity and expertise, enables country infrastructure and retains the talent to generate innovation at home is crucial. It’s about Human Rights, Social Justice and Equity.

In the short term, developing countries need to be able to produce vaccines and access them equitably. This includes relaxing the World Trade Organization’s Trade Related Access to International Property Rights to enable countries to produce vaccines on site.

In the long term, international collaboration across nations is urgent. For example, the Sputnik-V vaccine program in Argentina involves cooperation between the Gamaleya Institute, the Russian Investment Fund and a national pharmaceutical, Richmond Lab, to develop and produce vaccines for Argentina and the southern cone. This type of cooperation is strategic to expand vaccine production and enhance technology investment in developing countries.